AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Barramundi Group

Investor Presentation Aug 30, 2022

8174_rns_2022-08-30_dbe3eafb-a454-4f90-93dd-993cda268320.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

1H 2022 Report Presentation

BARRAMUNDI GROUP LTD 30 AUG 2022

Building an Asia Pacific aquaculture leader

Barramundi Group builds a fully integrated aquaculture leader with a premium product in a high growth market

retailers.

Growth Securing capacity for growth

Barramundi group is securing capacity to grow from 2,000 tonnes capacity in 2021 to 7,000 tonnes in 2026 and further to a long term target of 75,000 tonnes.

Highlights 1H 2022

- There was a reduction in sales tonnage from 1,012 tonnes in 1H 2021 to 930 tonnes in 1H 2022. 1H 2022 sales million in 1H 2021. • Net profit for 1H 2022 was -\$12m

-

1H 2022 Profit and Loss (Unaudited)

  • companies.
    -
    -
    -
  • loans in August 2021.
  • Australia.
1H 2022 Profit and Loss
(Unaudited)
Revenue
1H
2022
of
SGD
16.9
million
(1H
2021
:
SGD
17.1
million).
Harvest
volumes
Actual Proforma Actual
were
up
from
973
to
986
tonnes
(WFE).
1H 2022 1H 2022 1H 2021
Unaudited
\$
Unaudited
\$
Unaudited
\$
Change
in
accounting
estimates
from
1
January
2022
to
the
full
capitalisation
method
for
biological
assets
in
order
to
be
aligned
with
the
reporting
by
other
listed
seafood
companies. Revenue 16,919,539 16,919,539 17,104,383
All
direct
and
indirect
costs
of
producing
the
biomass
are
being
capitalised
as
o
Other income
Raw materials and consumables
323,864
(12,634,500)
323,864
(12,789,528)
1,349,516
(10,948,784)
opposed
to
just
juvenile
and
feed
costs
as
was
done
prior
to
2022.
Farm personnel expense (1,693,918) (4,353,337) (4,515,204)
"Pro
forma"
income
statement
for
the
first
half
of
2022,
based
on
the
accounting
o
Fair value (loss)/gain on biological assets (7,267,085) (4,381,238) (50,649)
estimates
used
in
2021.
Fish mortalities
Depreciation
(1,720,884)
(849,930)
(1,074,139)
(1,568,075)
(1,254,897)
(1,863,043)
Cost
of
raw
materials
and
consumables
utilized
in
the
period
increased
by
SGD
1.8
o
Amortisation (282,151) (282,151) (282,150)
million
from
SGD
10.9
million
following
biomass
adjustments
in
Australia,
increase
Administrative expense (3,236,445) (3,236,445) (3,074,426)
in
production
costs
and
higher
costs
of
raw
materials
in
Fassler.
Distribution expense
Finance expense
(1,003,021)
(479,357)
(1,003,021)
(479,357)
(1,241,063)
(1,241,896)
Change
in
fair
value
adjustment
in
the
profit
and
loss
statement
represents
the
reduction
Loss before tax (11,923,888) (11,923,888) (6,018,213)
in
the
positive
fair
value
difference
between
fair
value
of
the
biomass
and
value
of
the
biomass
at
cost.
Income tax credit (29,560) (29,560) -
Change
in
fair
value
adjustment
of
SGD
4.4
million
in
the
pro
forma
P&L
results
o
Net loss for the financial period (11,953,448) (11,953,448) (6,018,213)
from
the
change
in
capitalisation
method
and
an
increase
in
production
costs
caused
by
increases
in
feed
and
feed
freight,
higher
energy
costs,
lower
than
Other comprehensive income/(loss):
expected
production
results
and
stock
adjustments
from
fish
losses.
Items that may be reclassified subsequently to profit or loss:
-
Currency translation gain/(loss) on
Additional
administrative
charges
were
incurred
from
continuing
listing
costs.
translating foreign operations (100,112) (100,112) (502,400)
Additionally,
new
sites
costs
are
incurred
in
the
application
of
leases
for
new
sites
in
Australia. Total comprehensive loss for the financial period (12,053,560) (12,053,560) (6,520,613)
(Loss)/profit attributable to:
Distribution
costs
fell
due
to
a
write
back
of
accruals
for
distribution
costs
following
Covid
Owners of the Company (12,052,820) (12,052,820) (6,420,460)
restrictions
in
China
which
limited
the
sales
and
distribution
of
the
products.
Non-controlling interests 99,372 99,372 402,247
(11,953,448) (11,953,448) (6,018,213)
Total comprehensive (loss)/income
Finance
costs
were
reduced
by
SGD
0.8
million
compared
to
the
first
half
of
2021,
attributable to:
Owners of the Company
following
the
repayment
or
conversion
to
equity
in
respect
of
the
Company's
convertible
(12,152,932)
99,372
(12,152,932)
99,372
(6,922,860)
402,247
loans
in
August
2021.
(12,053,560)
Non-controlling interests (12,053,560) (6,520,613)

1H 2022 Balance Sheet (Unaudited)

  • Singapore.
  • Singapore.
1H 2022 Balance Sheet (Unaudited)
Total
assets
as
at
30
June
2022
was
SGD
89.0
million
and
shareholders'
equity
was

SGD
39.6
million.
30 Jun 2022
Unaudited
\$
30 Jun 2021
Unaudited
\$

In
this
half
year,
capex
spending
was
made
towards
the
Brunei
site
and
a
new
vessel
in
ASSETS
Singapore. Current assets
Cash and cash equivalents
Trade and other receivables
17,652,049
5,921,297
27,354,041
6,861,056
There
was
a
reduction
in
biological
assets
carried
at
fair
value
following
a
decrease
in

biomass
and
on
the
back
of
a
slight
reduction
in
average
net
selling
price.
Inventories
Biological assets
6,029,902
16,903,863
46,507,111
3,096,347
22,886,826
60,198,270

Cash
continued
to
be
invested
in
the
operations
to
build
biomass,
capex
spending
and
repayment
of
bank
borrowings.
Non-current assets
Property, plant and equipment
Intangible assets
28,514,321
10,893,232
27,523,071
13,957,533

An
additional
banking
facility
of
SGD
5
million
was
secured
for
business
funding
in
Biological assets
Deferred income tax assets
977,858
2,096,262
42,481,673
1,162,866
2,697,033
45,340,503
Singapore. Total assets
LIABILITIES
88,988,784 105,538,773
Current liabilities
Trade and other payables
Employee benefits
9,783,424
445,985
9,549,495
564,931
Borrowings
Deferred capital grants
9,159,238
127,924
35,858,182
75,290
Income tax payables 39,908
19,556,479
-
46,047,898
Non-current liabilities
Employee benefits
- 112,415
Borrowings
Deferred capital grants
21,541,858
4,767,594
26,630,009
5,129,724
Provision for reinstatement
Deferred income tax liabilities
55,980
3,418,940
55,980
4,050,756
Total liabilities 29,784,372
49,340,851
35,978,884
82,026,782
Net assets 39,647,933 23,511,991
EQUITY
Share capital
Other reserves
153,913,373
(2,724,008)
105,154,252
(326,470)
Accumulated losses
Non-controlling interests
(117,289,178)
5,747,746
(85,735,353)
4,419,562

1H 2022 Cash Flow Statement (Unaudited)

1H 2022 Cash Flow Statement (Unaudited)
There
was
a
net
decrease
of
SGD
10.7
million
in
the
cash
position
for
this
half
year
to
YTD 30 June 2022 YTD 30 June 2021
17.7
million.
A
negative
cashflow
was
caused
by
a
combination
of
lower
revenue,
Unaudited
\$
Unaudited
\$
reduced
harvest
tonnage,
increase
in
raw
materials
and
production
cost,
growth
capex
spending
for
Brunei
and
the
new
vessel
for
Singapore.
Additional
funding
was
secured
Cash flows from operating activities
Loss before tax
(11,923,888) (6,018,213)
through
a
bank
loan
for
the
Singapore
operations.
Adjustments for:
-
Fair value adjustment on biological assets
7,267,085 50,649
-
Amortisation of government grant
(89,445) (167,234)
-
Depreciation of property, plant and equipment and right-of-use assets
796,041 1,809,154
53,889
-
Depreciation of biological assets
-
Property, plant and equipment written-off
53,889
20,624
-
-
Amortisation of intangible assets
282,151 282,150
-
Employee share option expenses
-
Interest expense
95,291
488,253
185,226
1,241,896
-
Interest income
(8,896) (53,090)
-
Provision for employee benefits
14,395
(3,004,500)
16,340
(2,599,233)
Changes in working capital:
-
Biological assets
(3,692,583) (686,228)
-
Inventories
-
Trade and other receivables
(2,517,576)
1,292,056
(1,119,604)
(49,271)
-
Trade and other payables
408,554 114,141
Cash used in operations, representing net cash used in operating activities (7,514,049) (4,340,195)
Cash flows from investing activities
Additions to property, plant and equipment
Interest received
(4,146,976)
8,896
(3,828,203)
53,090
Net cash used in investing activities (4,138,080) (3,775,113)
Cash flows from financing activities
Proceeds from borrowings 1,839,621 9,381,634
Repayment of lease liabilities
Interest paid
(454,749)
(488,253)
(643,842)
(1,241,896)
Redemption of redeemable convertible preference shares - (1,234,223)
Net cash provided by financing activities 896,619 6,261,673
Net (decrease)/increase in cash and cash equivalents (10,755,510) (1,853,635)
Cash and cash equivalents
Beginning of the financial year 28,482,011 29,327,259
Effects of currency translation on cash and cash equivalents
End of the financial year
(74,452)
17,652,049
(119,583)
27,354,041

1H 2022 Key Financials & Highlights- Australia • Net sales for Australia were reduced by SGD 1.5 million following reduced harvest

-

Harvest tonnage (T) 729 811
Biomass end of quarter (T) 1,562 1,696

1H 2022 Key Financials & Highlights - Singapore • Net sales for 1H 2022 increased by SGD 0.3 million on the back of higher harvest volume. With the relaxation of Covid restrictions, there was an uplift in B2B sales to

2021 to SGD 13.24.

Actual Actual
1H 2022 1H 2021
Net sales (S\$) (in million) \$2.66 \$2.27
Net selling price (S\$) \$13.24 \$14.05
Harvest tonnage (T) 257 162
Biomass end of quarter (T) 236 541

  • advanced stages. Net sales was from trial harvest.
Harvest tonnage (kg) 25 -
Biomass end of quarter (T) 80 3

1H 2022 Key Financials & Highlights- Fassler • Fassler's revenue increased by 18% to SGD 6.8 million in 1H 2022 with a more

customers gradually from Q2 2022.

Outlook

  • Barramundi prices are expected to be stable, gradual price increase for other processed fish
  • Harvest volume in 2022 expected to be similar to 2021
  • Expected cost inflation, particularly feed
  • Process for funding of Australian expansion to commence in Q3 2022

Financial Calendar

Q3 2022 Business update 29 November 2022
2H 2022 Results 28 February 2023
2022 Full year results 28 April 2023

Appendix

Alternative performance measures Barramundi Group Ltd discloses alternative performance measures as a supplement to the financial statements prepared in accordance with IFRS. Such performance measures are commonly used by analysts, investors and other stakeholders to evaluate the performance of the company and its businesses. The measures are provided to give an enhanced insight into the operations of the company and its businesses. Operating EBITDA and/or Operational EBITDA is net profit/(loss) before amortization and depreciation expenses, finance costs, provision for income taxes, excluding new sites, one-off non-operational costs and fair value adjustments on biological assets. Operating EBIT and/or Operational EBIT is net profit/(loss) before finance costs, provision for income taxes, excluding new sites, one-off non-operational costs and fair value adjustments on biological assets. Operating EBT and/or Operational EBT is net profit/(loss) before provision for income taxes, excluding new sites, one-off non-operational costs and fair value adjustments on biological assets. Operating net profit/(loss) and/or Operational net profit/(loss) is net profit/(loss) excluding new sites, one-off non-operational costs and fair value adjustments on biological assets.

Talk to a Data Expert

Have a question? We'll get back to you promptly.